Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Combined COVAX, PPV23, and IIV4
NCT05079152Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- May 2021
- Primary completion
- May 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of inactivated SARS-CoV-2 vaccine (WIBP) in coronavirus disease 2019 (COVID-19), sponsored by China National Biotec Group. Status: unknown.
02
Drugs
inactivated SARS-CoV-2 vaccine (WIBP)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05079152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079152.